What is Leqembi? The first Alzheimer's treatment approved today in Saudi Arabia
The Saudi Food and Drug Authority (SFDA) announced today the official approval of Leqembi, the first Alzheimer's treatment available in Saudi Arabia. This approval marks a significant milestone in addressing Alzheimer's, a progressive brain disorder that affects memory and thinking skills.
Leqembi is specifically indicated for patients experiencing mild cognitive impairment or mild dementia caused by Alzheimer's, who have either no copies or just one copy of a particular gene variant known as apolipoprotein E4 (ApoE4).
How Leqembi Works: Targeting the Root Cause
Leqembi represents an innovative approach to treating Alzheimer's. Unlike many existing therapies that only ease symptoms, this drug aims to slow the actual progression of the disease.
It is a biologic therapy developed using monoclonal antibody technology, a sophisticated method that creates lab-produced molecules designed to target specific proteins in the body.
In this case, Leqembi works by targeting beta-amyloid proteins, which tend to build up in the brains of Alzheimer's patients and form sticky clumps called plaques. These plaques are widely believed to contribute to the cognitive decline seen in the disease.
by Taboola
by Taboola
Sponsored Links
Sponsored Links
Promoted Links
Promoted Links
You May Like
Patrocinio: Unsold Furniture Liquidation 2024 (Prices May Surprise You)
Unsold Furniture | Search Ads
Learn More
Undo
Specifically, brain plaques, known as amyloid plaques, are abnormal clumps of protein fragments called beta-amyloid that build up in the brain, especially in people with Alzheimer's.
These plaques interfere with the normal communication between nerve cells (neurons), disrupting brain function. By helping reduce the formation of these harmful plaques, Leqembi seeks to protect brain function and slow cognitive decline over time.
The treatment is given through an intravenous infusion every two weeks, allowing the drug to circulate and act within the brain.
Proven Effectiveness Backed by Clinical Studies
Before approving Leqembi, the SFDA thoroughly reviewed evidence of its safety, effectiveness, quality, and compliance with regulatory standards. Clinical trials revealed that Leqembi significantly slows the progression of Alzheimer's disease compared to a placebo. The effectiveness was measured using established clinical scales that assess memory, thinking, and daily functioning abilities.
However, like all medications, Leqembi can cause side effects. The most commonly reported include:
Headaches
Reactions related to the infusion process
Amyloid-related imaging abnormalities (ARIA), a term that refers to unusual changes detected in brain MRI scans. These abnormalities may include swelling (cerebral edema) or tiny brain bleeds (microhemorrhages).
Because ARIA can only be detected through brain scans, careful monitoring is essential throughout treatment.
Safety First: The Need for Careful Patient Monitoring
The SFDA stresses the importance of ongoing patient monitoring during treatment. Before starting Leqembi, patients must be tested for their ApoE4 gene status, as this influences the risk of side effects.
Those with two copies of the ApoE4 gene are not currently eligible for the treatment due to a higher likelihood of complications.
Additionally, the pharmaceutical company responsible for Leqembi is required to track how the drug performs once it is in use (post-marketing surveillance). They must regularly submit updated reports on safety and effectiveness to the SFDA. A comprehensive risk management plan is also mandatory to ensure the treatment is used safely and responsibly.
Advancing Healthcare with
Biotechnology
in Saudi Arabia
The approval of Leqembi reflects the SFDA's commitment to expanding access to advanced and high-quality medical treatments, especially those developed through cutting-edge biotechnological methods. Biotech therapies like Leqembi represent a rapidly growing field in medicine, offering new hope for diseases that previously had limited treatment options.
About the SFDA
Established in 2003 under the Council of Ministers' resolution, the Saudi Food and Drug Authority is an independent regulatory body directly reporting to the President of the Council of Ministers. Its main mission is to safeguard public health by ensuring the safety and quality of food, medicines, biological and chemical substances, medical devices, and cosmetics. The SFDA oversees all procedures related to these products, aiming to protect both human and animal health throughout the Kingdom.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
an hour ago
- Time of India
Josh Hines Allen opens up about his son Wesley's brave cancer battle and inspiring recovery
Josh Hines Allen opens up about his son Wesley's brave cancer battle and inspiring recovery (Image Via X) It all started with a phone call. Josh Hines‑Allen, a star defensive end for the Jacksonville Jaguars, found out early in 2025 that his seven‑year‑old son, Wesley, had acute promyelocytic leukemia. For months they fought in hospital rooms, holding onto hope. The family stayed quiet at first, sharing little public detail. Now the prayers are working. Wesley is back to being a kid; playing, laughing, and even heading back to school. The NFL world is watching, hoping, and lifting him up every day. Josh Hines‑Allen's son Wesley fought Leukemia with strength beyond his years Wesley was diagnosed in January 2025 in Jacksonville, Florida, after he had a high fever and began bleeding from a tooth, which led his parents to seek medical help at Nemours Children's Health, Jacksonville. His dad, Josh Hines‑Allen, missed the last game of the 2024 season due to this crisis. Over the next six to seven months, Wesley underwent chemotherapy at Nemours, a rigorous period that his parents described as the hardest time of their lives. In July 2025, Josh announced via social media that Wesley is now in full remission and nearing the end of his treatment, with the final chemotherapy phase planned to wrap up by the end of August in Jacksonville. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like 15 Most Beautiful Female Athletes in the World! Learn More Undo Josh shared, 'We recently received the good news that Wesley is on his way to a full recovery,' and Kaitlyn, his wife, added, 'He's swimming every day … running around … playing sports' like any seven‑year‑old. Josh added, 'He's got back to being the big brother that he is'. Josh and Kaitlyn Hines‑Allen turned their son's battle into a mission to help others Inspired by their son's courage, Josh and Kaitlyn have started a charity effort through their nonprofit foundation, Four One For All. In 2025 they created a campaign called Four One For Hope. Each month of the NFL season, they will support a different childhood cancer nonprofit: Nemours Children's Health in September, the American Cancer Society in October, Ronald McDonald House Charities of Jacksonville in November, and the National Pediatric Cancer Foundation in December. Josh has said their goal is to help other families feel the same love and support they received. He praised his team's coaches and staff for checking in with him by asking, 'How's Wesley?' rather than just, 'How are you?' —showing real care for his family. With Wesley winning his battle and the Hines‑Allen family giving back, the NFL world continues to stand behind them—with hope, with prayers, and with respect for a brave young boy's strength. Also Read: Josh and Kaitlyn Hines Allen launched the 'Four One For Hope' campaign to support childhood cancer nonprofits. Catch Rani Rampal's inspiring story on Game On, Episode 4. Watch Here!
Time of India
an hour ago
- Time of India
Civil surgeon urges Nashik Municipal Corporation to provide primary care in civic hospitals
Nashik: Charudatta Shinde, the civil surgeon of the Nashik Civil Hospital, wrote to the medical officer of Nashik Municipal Corporation to avoid the unnecessary referral of patients from urban health centres to the hospital. The hospital is primarily meant to treat patients coming in from 15 talukas and even from neighbouring districts. The civil surgeon pointed out that there are referrals from the corporation hospitals for ailments that can be handled there. Even beggars, homeless people, and others are sent to the Civil Hospital for treatment. "We will not say no to anybody seeking treatment here. However, it has to be noted that we receive funds from the state and district for medicines in proportion to the population of the district. We are treating patients from Palghar, Dhule, and Ahilyanagar districts as well. The number of patients from Nashik city, which has separate funds for medicine, should be handled by NMC hospitals," said Shinde. T by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Living perfectly well without American goods': Why more Chinese shoppers support local brands CNA Read More Undo he Civil Hospital caters to over 4 lakh patients annually. Shinde also noted that beggars, homeless people, and destitutes often arrive at the Civil Hospital, most of them without any primary treatment. The NMC health authorities, however, said the number of direct referrals from the NMC hospitals is relatively low. "It could be the case that people from all sides of the city find the Civil Hospital more accessible and, therefore, the patients, even without coming to the NMC establishments, directly go to that hospital. We have good hospitals, like the ones at Nashik Road, Indira Gandhi Hospital at Panchavati, and at Satpur. Patients are referred only in very serious cases," an officer said.
Time of India
an hour ago
- Time of India
Bhandewadi biomedical waste plant operator gets Rs1.5L penalty notice
Nagpur: The Nagpur Municipal Corporation (NMC) has issued a show cause notice and proposed a penalty of Rs1.5 lakh on Super Hygienic Disposals Pvt Ltd — the operator of the city's sole Common Biomedical Waste Treatment Facility (CBWTF) at Bhandewadi — after untreated biomedical waste was found lying at the site for over 15 days. The glaring violation was found during a surprise inspection on July 15, 2025, by additional municipal commissioner Vasumana Pant, deputy municipal commissioner (solid waste management) Rajesh Bhagat, and other senior officials. The team found large quantities of non-processed biomedical waste — including blood-soaked items, used syringes, and contaminated plastic — dumped inside the facility. According to the show cause notice issued by Bhagat on Wednesday, the accumulation of untreated waste has compromised the processing capacity of the facility. As per clause 14 of the concession agreement signed on August 12, 2004, the operator is mandated to dispose of biomedical waste within 48 hours of collection, in line with Maharashtra Pollution Control Board (MPCB) guidelines. "However, during the visit, it was observed that biomedical waste had been lying at the project site for approximately 15 days," states the notice, adding that this amounts to a clear violation of the agreement. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like 5 Books Warren Buffett Wants You to Read In 2025 Blinkist: Warren Buffett's Reading List Undo Citing clause 39 of the contract, which allows for a daily penalty of Rs10,000 for such violations, the NMC has proposed a total fine of Rs1.5 lakh. The operator has been directed to respond within 24 hours with an explanation and an immediate action plan, failing which will invite further action. Officials also suspect that the operator may have been deliberately stockpiling recyclable plastic components, such as saline bottles, for resale without prior sterilization — another serious breach of biomedical waste handling norms.
